IZI Medical Products, LLC (“IZI”), a leading interventional radiology medical device company and portfolio company of Shore Capital Partners, LLC (“Shore”), is pleased to announce it has acquired RadioMed, the manufacturer of VISICOIL™ implantable fiducial markers, from IBA S.A.
“This represents IZI’s fourth add-on acquisition in the last 24 months and adds to our world-class portfolio of minimally invasive diagnostic and therapeutic products for the interventional radiology market,” said Greg Groenke, Chief Executive Officer, IZI Medical. “We believe that the VISICOIL™ fiducial marker is the industry leading solution due to its maximum soft-tissue fixation and minimal imaging artifact. We are excited to increase the market penetration of these products through RadioMed’s existing distribution channels and IZI’s direct sales force. These products are complementary to IZI’s existing Imaging Marker and Interventional Oncology portfolios.”
“IZI continues to pursue a highly targeted acquisition strategy as it focuses on building a tailored suite of products for the Interventional Radiologist,” said Don Pierce, a Partner of Shore Capital and Chairman of the Board of IZI. “We are excited about the direction IZI is headed and will continue to invest in resources to grow the platform.”
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
